Titania based generators for ac-225 generation

Patent metadata

Field	Value
Publication number	US-2022339292-A1
Application number	US-202217725409-A
Country	US
Kind code	A1
Filing date	Apr 20, 2022
Priority date	Apr 20, 2021
Publication date	Oct 27, 2022
Grant date	—

Abstract

In one aspect, the technology relates to a method of producing Ac, the method including preparing a phosphate-modified titania material to produce an ion-exchange material, contacting a solution including 229 Th with the ion-exchange material to produce a Th-loaded titania material, eluting the Th-loaded titania material with a wash solution to produce an eluted solution containing eluted compounds including 225 Ac, concentrating the eluted solution to generate eluted compounds including the 225 Ac, and separating the 225 Ac from the eluted compounds.

First claim

What is claimed is:

1 . A method of producing Ac, the method comprising:
preparing a phosphate-modified titania material to produce an ion-exchange material; contacting a solution including 229 Th with the ion-exchange material to produce a thorium-loaded ion-exchange material and a contacted solution; eluting the thorium-loaded ion-exchange material with a wash solution to produce an eluted solution of 225 Ac; and concentrating the eluted solution to generate eluted compounds; and separating the 225 Ac from other radioisotopes in the eluted compounds.

2 . The method of claim 1 , wherein preparing the phosphate-modified titania material comprises:
mixing titania with a phosphate solution to produce a diluted titania solution; stirring the diluted titania solution; extracting a phosphate-modified titania from the diluted titania solution by decanting the phosphate solution; washing the phosphate-modified titania to produce a washed phosphate-modified titania; and drying the washed phosphate-modified titania to produce a dried phosphate-modified titania.

3 . The method of claim 1 , wherein the phosphate solution comprises H 3 PO 4 .

4 . The method of claim 3 , wherein the phosphate solution comprises one of 1.0 M H 3 PO 4 , a range of 0.1-0.5 M H 3 PO 4 , a range of 1-5 M H 3 PO 4 , and a range of 5-10 M H 3 PO 4 .

5 . The method of claim 1 , wherein stirring the diluted titania solution comprises stirring the diluted titania solution at a speed in a range of 10 rpm-2000 rpm for a duration in a range of 0.1-100 h and at temperature in a range of 10-100° C.

6 . The method of claim 1 , wherein contacting the solution comprises contacting the solution with the phosphate-modified titania material in a column containing the phosphate-modified titania material.

7 . The method of claim 1 , further comprising evacuating a residual solution that includes 229 Th out of the column before contacting the column.

8 . The method of claim 7 , wherein evacuating the residual solution comprises:
drying the residual solution to create a solid residue; eluting the solid residue with an eluting solution to produce an eluted residue; passing the eluted residue through a recovering resin to recover 229 Th; and recovering 229 Th.

9 . The method of claim 9 , wherein eluting solution comprises HNO 3 .

10 . The method of claim 10 , wherein eluting solution comprises HNO 3 in a range of 0.01-10 M.

11 . The method of claim 8 , wherein the recovering resin comprises a UTEVA resin.

12 . The method of claim 8 , wherein recovering 229 Th comprises recovering 229 Th at a rate equal to or greater than 99.253±0.004%.

13 . The method of claim 8 , wherein the eluting comprises using an eluant comprising a HOA/NaOA solution.

14 . The method of claim 1 , wherein separating the produced 225 AC comprises:
separating 225 AC from 228 Ra; and collecting the separated 225 AC to obtain a 225 AC product.

15 . A pharmaceutical composition comprising the 225 Ac product generated claim 14 .

16 . The pharmaceutical composition of claim 15 , wherein the 225 AC is conjugated to an antibody.

17 . A method of treating cancer in a patient comprising administering to the patient the pharmaceutical composition of claim 15 .

18 . The method of claim 17 , wherein the cancer is breast cancer, a leukemia, a lymphoma, brain cancer, liver cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, or bone cancer.

19 . A method for separating Ac from a Ra/Ac mixture, the method comprising:
concentrating the Ra/Ac mixture in a first solution; passing the Ra/Ac mixture through a first resin; adding a second solution; passing the Ra/Ac mixture through a second resin; and separating Ra from Ac to produce separated Ra and separated Ac.

20 . A 225 Ac producing generator, comprising:
a first portion of the generator; a column body defining an interior chamber; a first access port at the first portion of the generator providing access to the interior chamber; and a phosphate-modified titania material within the interior chamber, the phosphate-modified titania material loaded with an amount of 229 Th.

Assignees

• Terrapower Llc

Inventors

• Czerwinski Ken
• Chatterjee Sayandev
• Liao Zuolei
• Kim Pyoungchung
• Vlasenko Vladislav P
• Ludwig Russell C
• Dunckley Christopher P

Classifications

• G21G1/001

  Recovery of specific isotopes from irradiated targets · CPC title

• G21G1/0005 Primary

  Isotope delivery systems (use of radioisotopes as tracers G21H5/02) · CPC title

• G21G2001/0089

  Actinium · CPC title

• A61K51/00

  Preparations containing radioactive substances for use in therapy or testing in vivo · CPC title

• C22B60/0295 Primary

  obtaining other actinides except plutonium · CPC title